A small, prospective, observational study of 313 patients with small-cell lung cancer found no association between aspirin use and survival or metastasis.14
A meta-analysis of 18 observational studies that included 19,835 patients similarly found no overall association between aspirin use and incidence of lung cancer, though 2 case-control studies with heterogeneity demonstrated a significantly decreased risk of disease (OR, 0.71; 95% CI, 0.56-0.91).15
A prospective cohort study of 22,071 men from the Physicians’ Health Study (ClinicalTrials.gov Identifier: NCT00000500) demonstrated that the risk of lethal prostate cancer was reduced with regular current (HR, 0.68; 95% CI, 0.52-0.89) or past aspirin use (HR, 0.54; 95% CI, 0.40-0.74). Among men with nonlethal prostate cancer, current post-diagnosis aspirin use reduced the risk of developing lethal disease (HR, 0.68; 95% CI, 0.52-0.90) and overall mortality (HR, 0.72; 95% CI, 0.61-0.90).16
A meta-analysis of 24 observational studies demonstrated that regular aspirin use significantly reduced OS (RR, 0.86; 95% CI, 0.81-0.92) and prostate cancer–specific mortality (RR, 0.83; 95% CI, 0.75-0.91), particularly with longer duration of use.17
A case-control study of 823 and 1034 men with and without prostate cancer, respectively, demonstrated that daily use of aspirin for over 3 years significantly reduced the risk of advanced prostate cancer (T3: OR, 0.35; 95% CI, 0.17-0.73; T4: OR, 0.22; 95% CI, 0.08-0.60) and disease recurrence among African American men.18
A meta-analysis of 5 observational studies including 332,660 adults found no association between aspirin use and the risk of multiple myeloma (MM).19
A prospective analysis of the Health Professionals Follow-up Study and Nurses’ Health Study that included 2,395,458 person-years demonstrated that regular use (at least 5 times per week) of 325 mg of aspirin significantly reduced risk of MM by 39% (HR, 0.61; 95% CI, 0.39-0.94). Continuous regular use of 11 years or longer was also associated with lower risk of MM (HR, 0.63; 95% CI, 0.41-0.95).20
- Cao Y, Nishihara R, Wu K, et al. The population impact of long-term use of aspirin and risk of cancer. JAMA Oncol. 2016;2:762-9.
- Drew DA, Chin SM, Gilpin KK, et al. Aspirin intervention for the reduction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials. 2017;18:50.
- Coyle C, Cafferty FH, Rowley S, et al; Add-Aspirin Investigators. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56-64.
- Bibbins-Domingo K; U.S. Preventative Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventative Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:836-45.
- Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force [internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015. Report No.: 15-05228-EF-1.
- Frouws MA, Rademaker E, Bastiaannet E, et al. The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. Eur J Cancer. 2017;77:24-30.
- Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not pre-diagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64:1419-25.
- Frouws MA, Bastiaannet E, Langley RE, et al. Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies: an observational study. Br J Cancer. 2017;116:405-13.
- van Staalduinen J, Frouws M, Reimers M, et al. The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients. Br J Cancer. 2016;114:1053-59.
- Risch HA, Lu L, Streicher SA, et al. Aspirin use and reduced risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2017;26:68-74.
- Mc Menamin UC, Cardwell CR, Hughes CM, Murray LJ. Low-dose aspirin use and survival in breast cancer patients: a nationwide cohort study. Cancer Epidemiol. 2017;47:20-7.
- Lu L, Shi L, Zeng J, Wen Z. Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants.. Oncotarget. 2017 Mar 17. doi: 10.18632/oncotarget.16315 [Epub ahead of print]
- Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies. Breast Cancer Res Tret. 2015;150:199-207.
- Maddison P. Effects of aspirin on small-cell lung cancer mortality and metastatic presentation. Lung Cancer. 2017;106:67-9.
- Jiang HY, Huang TB, Xu L, et al. Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis. PLoS ONE. 2015;10:e0122962.
- Downer MK, Allard CB, Preston MA, et al. Regular aspirin use and the risk of lethal prostate cancer in the Physicians’ Health Study. Eur Urol. 2017 Feb 8. doi: 10.1016/j.eururo.2017.01.044 [Epub ahead of print]
- Huang TB, Yan Y, Guo ZF, et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol. 2014;46:1715-28.
- Smith CJ, Dorsey TH, Tan W, Jordan SV, Loffredo CA, Ambs S. Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African-American men. Cancer Epidemiol Biomarkers Prev. 2017 Mar 14. doi: 10.1158/1055-9965.EPI-16-1027 [Epub ahead of print]
- Lee SF, Ng TY, Wong FC, Tung SY. Aspirin and risk of multiple myeloma in adults: a systematic review and meta-analysis. Leukemia Res Rep. 2017;7:23-8.
- Birmann BM, Giovannucci E, Rosner B, Colditz GA. Regular aspirin use and risk of multiple myeloma: a prospective analysis in the Health Professionals Follow-up Study and Nurses’ Health Study. Cancer Prev Res (Phila). 2014;7:33-41.